Novo Nordisk Settles With Pfizer On Patent Infringement Suit

    PRINCETON, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Novo Nordisk Inc.
 today announced the company has settled a lawsuit against Pfizer claiming
 that Pfizer's product Exubera(R) infringed patents owned by Novo Nordisk.
 The patents cover inhaled insulin treatment for diabetes.
 
     The lawsuit was originally filed in August 2006 in United States
 Federal Court in the Southern District of New York.
 
     Novo Nordisk is a healthcare company with an 84-year history of
 innovation and achievement in diabetes care. The company has the broadest
 diabetes product portfolio in the industry, including the most advanced
 products within the area of insulin delivery systems. In addition to
 diabetes care, Novo Nordisk has a leading position within areas such as
 hemostasis management, growth hormone therapy, and hormone therapy for
 women. Novo Nordisk's business is driven by the Triple Bottom Line: a
 commitment to economic success, environmental soundness, and social
 responsibility to employees and customers. With headquarters in Denmark,
 Novo Nordisk employs more than 25,000 employees in 79 countries, and
 markets its products in 179 countries. Novo Nordisk's B shares are listed
 on the stock exchanges in Copenhagen and London. Its ADRs are listed on the
 New York Stock Exchange under the symbol 'NVO'. For global information,
 visit novonordisk.com; for United States information, visit
 novonordisk-us.com.
 
 
 

SOURCE Novo Nordisk Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.